Valneva Stock Hovers at Year Low as EMA Tightens IXCHIQ Monitoring and Pipeline Risks Mount

Valneva shares fall to €2.22 as EMA tightens IXCHIQ safety surveillance; Q1 revenue slides, cost cuts announced, while Pfizer-partnered Lyme vaccine VLA15 offers future hope.

The latest chapter in Valneva’s prolonged slide came into focus on Friday, when the stock closed at €2.22, down nearly 3% in a single session and leaving it just 4% above its 52-week floor of €2.13 from early May. The immediate catalyst was fresh regulatory pressure: the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee confirmed new safety surveillance protocols for Valneva’s Chikungunya vaccine IXCHIQ during its early-July meeting, with a revised assessment report published on July 7.

That development adds a layer of operational uncertainty to an already strained business. IXCHIQ has been one of only three commercial products in Valneva’s portfolio, but the vaccine has been under a cloud since reports of severe adverse reactions in older patients and a younger adult who received the shot alongside other immunisations. The EMA has already restricted the European label to patients aged 12 and over with a high infection risk. Across the Atlantic, Valneva withdrew its US marketing application after the FDA halted a clinical trial.

Year to date, the share price has fallen 42.18%, and over a 12?month period the loss is 13.05%. From its August 2025 peak of €5.16, the stock has shed 57% of its value. The steep decline reflects more than regulatory headwinds: Valneva’s first?quarter results were poor, with revenue sliding to €30.9 million and a net loss widening to €32.1 million as all three core products – IXIARO, DUKORAL and IXCHIQ – underperformed expectations. Management has responded by slashing the full?year product revenue forecast to between €135 million and €150 million (total revenue of €145 million to €160 million) and announcing a severe cost?cutting programme that includes up to 15% of staff and a 25%–35% reduction in operating expenses. A separate technical overhang appeared when a lock?up agreement on shares issued in April expired on July 2, freeing additional stock for trading.

The technical picture offers little comfort. Valneva trades 7% below its 50?day moving average of €2.39 and 36% below the 200?day average of €3.48. The 14?day relative strength index sits at 37.9, edging toward oversold territory but not yet signalling a convincing reversal. A 30?day annualised volatility reading of 30.53% hints that big intraday moves are likely to persist in the near term.

Against this backdrop, the company’s pipeline has become the central narrative for investors looking past the current turmoil. The Lyme disease vaccine candidate VLA15, developed in partnership with Pfizer, produced strong secondary efficacy data from a fourth?dose analysis in its Phase?3 programme, even though the primary statistical endpoint was narrowly missed. CEO Thomas Lingelbach has pointed to Pfizer’s communications that a regulatory submission is planned for the second half of 2026, with a market launch potentially possible in 2027. The second clinical asset, the Shigella vaccine S4V2, is advancing in a Phase?2 trial with initial data expected in 2026. A possible US Department of Defense contract for IXIARO also remains on the table, though no fixed date for any of these catalysts has been set.

Until one of those milestones crystallises, Valneva’s stock will remain hostage to sentiment and headline risk. The support at €2.13 is the last clear floor; if it breaks, further downside is likely. Should the level hold and the pipeline story gain conviction – particularly around VLA15’s path to submission – the technical oversold reading could provide the springboard for a rebound. For now, the stock is caught between a deteriorating commercial base and a long?dated pipeline that has yet to deliver a definitive turning point.